Dental technology company vVardis, headquartered in Zug, Switzerland, announced a significant rise in first‑half revenue in its recent filing for an initial public offering on the New York Stock Exchange. The filing shows the company generated $28.6 million in revenue for the six months ended June 30 2026, more than three times the $9.1 million reported a year earlier.
Financial performance and loss reduction
Along with the revenue boost, vVardis narrowed its net loss to $27.8 million, improving from a $32.1 million loss in the comparable period of 2025. The company attributes the stronger top line to broader adoption of its non‑invasive early‑cavity treatment platform, which it says has been sold to over 20,000 of the roughly 110,000 general dental practices in the United States.
Backers and market context
The filing notes that vVardis counts healthcare investor OrbiMed, dental‑service network Heartland Dental, and affiliates of Apollo Global Management among its investors. Analysts observing the filing point out that, while the overall US IPO market remains selective after a robust start to the year, healthcare and pharmaceutical firms have largely withstood broader macro‑economic uncertainty.
Medical‑device maker Centinel Spine also filed for an IPO this week, underscoring continued investor interest in health‑care‑related offerings despite tighter valuation scrutiny.
Use of IPO proceeds
According to the prospectus, vVardis intends to allocate the proceeds from the offering to working capital, operating expenses, and capital expenditures that will support continued product development and market expansion.
Underwriters and listing details
The company has engaged a consortium of banks—including Goldman Sachs, J.P. Morgan, William Blair, UBS Investment Bank, Deutsche Bank Securities, and Apollo Global Securities—to underwrite the offering. vVardis plans to list its shares on the NYSE under the ticker symbol “VVVV.”
Founded by dentist sisters Haley Abivardi and Goly Abivardi, vVardis focuses on minimally invasive treatments that aim to halt early‑stage cavities before they require drilling. The firm’s growth trajectory reflects a broader trend of dental professionals seeking technology‑driven solutions that preserve tooth structure and improve patient outcomes.
Outlook
With a growing customer base and backing from prominent investors, vVardis appears positioned to capitalize on the expanding demand for conservative dental care. The upcoming IPO will provide the capital needed to scale operations, enhance research and development, and deepen its presence across the United States.
Original reporting: Appleton, WI News Feed (HLL/CB) — read the source article.
